在结构性心脏病介入器械全球竞争格局中，瓣膜病是核心细分赛道，细分主动脉瓣、二尖瓣、三尖瓣三大技术赛道，各赛道疾病特征、技术门槛、国内外企业布局差异显著。主动脉瓣赛道发展成熟，爱德华、美敦力、雅培海外巨头先发优势突出，启明、微创、沛嘉等国产企业完成技术对标，实现大规模国产替代；二尖瓣赛道处于快速放量期，外资TEER产品长期领跑，德晋、捍宇等本土修复器械实现商业化突围；三尖瓣属于行业蓝海赛道，外资修复、置换产品临床数据积累有限，汇禾医疗K-Clip作为国内首款获批瓣环成形系统，形成独家本土化技术优势。
以爱德华、雅培、美敦力组成的海外企业与启明、德晋、汇禾为代表的国产创新梯队，依托各自赛道核心技术、全管线布局、临床循证体系、本土化服务形成差异化竞争力，共同推动全球瓣膜介入行业持续迭代。
展望未来，主动脉瓣、二尖瓣市场竞争将趋于常态化，三尖瓣赛道将成为行业核心增长极，汇禾代表的国产原创技术将打开全新增长空间。海外巨头成熟运营模式、国内企业本土化创新路径互为行业发展样板，双向参考能够推动全球结构性心脏病瓣膜产业均衡发展，助力行业实现长期可持续扩容。
In the global competitive landscape of structural heart disease interventional devices, valvular heart disease constitutes the core sub-track, which is further divided into three major technical segments: aortic valve, mitral valve and tricuspid valve. These segments differ markedly in disease characteristics, technical barriers and layout strategies of domestic and foreign manufacturers. The aortic valve track is highly mature, with overseas giants Edwards Lifesciences, Medtronic and Abbott holding first-mover advantages. Domestic players including Venus Medtech, MicroPort and Peijia Medical have achieved technical parity and large-scale import substitution. The mitral valve track is in a rapid growth phase; foreign TEER devices have long dominated the market, while domestic repair products developed by Djn Medical and HanYu Medical have achieved commercial breakthroughs. The tricuspid valve segment remains a blue ocean. Foreign repair and replacement devices lack sufficient clinical data accumulation, whereas HuiHe Medical’s K-Clip, China’s first approved tricuspid annuloplasty system, boasts exclusive localized technical strengths.
Overseas leaders Edwards Lifesciences, Abbott and Medtronic, alongside the domestic innovative echelon represented by Venus Medtech, Djn Medical and HuiHe Medical, have forged differentiated competitiveness through proprietary track-specific technologies, full product pipelines, clinical evidence systems and localized service networks, collectively driving continuous advancement in the global valvular intervention sector.
Looking ahead, competition in the aortic and mitral valve markets will enter a normalized stage, while the tricuspid valve track will emerge as the core growth engine of the industry. Original domestic technologies exemplified by HuiHe Medical will unlock brand-new growth potential. The mature operational frameworks of multinational enterprises and the localized innovation paths of Chinese manufacturers serve as mutual industry benchmarks. Cross-referencing these two models will foster balanced development of the global structural heart valvular device industry and support its sustained, long-term expansion.
如果您对中国心血管介入器械市场有进一步的研究需求，请联系我们：
沙利文 荆婧
E-mail: jing.jing@frostchina.com
